



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/580,511	02/13/2007	Elaine Fuchs	RCK0017US.NP	2375

26259 7590 03/17/2010
LICATA & TYRRELL P.C.
66 E. MAIN STREET
MARLTON, NJ 08053

EXAMINER

TON, THAIAN N

ART UNIT	PAPER NUMBER
----------	--------------

1632

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

03/17/2010

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

poreilly@licataandtyrrell.com

Office Action Summary	Application No. 10/580,511	Applicant(s) FUCHS ET AL.	
	Examiner Thaian N. Ton	Art Unit 1632	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 December 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5 and 7-16 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5 and 7-16 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicants' Amendment and Response, filed 12/3/09, has been entered. Claim 1 is amended; claims 1-5, 7-16 are pending and under current examination.

Election/Restrictions

Applicant's election of Group I (claims 1-16) in the reply filed on 12/1/08 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 1-5, 7-16 are under current examination.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 2-5 stand rejected under 35 U.S.C. 102(b) as being anticipated by US Pat No. 5,665,557 (Filed November, 1994; Issued September 9, 1997) as evidenced by Schrieber *et al* (**Haematologica**, 94(11): 1493-1501, 2009) and further evidenced by Akashi *et al.* (**Blood**, 101(2): 383-390, 2003). The prior rejection of claim 1 is *withdrawn* in view of Applicants' amendment to the claim which specifically recites slow-cycling cell markers.

Regarding the limitation in claims 2-5, the claims are product-by-process claims. Where, as here, the claimed and prior art products are identical or

substantially identical, or are produced by identical or substantially identical processes, the PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his claimed product. See *In re Ludtke*, supra. Whether the rejection is based on "inherency" under 35 USC 102, on "prima facie obviousness" under 35 USC 103, jointly or alternatively, the burden of proof is the same, and its fairness is evidenced by the PTO's inability to manufacture products or to obtain and compare prior art products. In *re Best*, *Bolton*, and *Shaw*, 195 USPQ 430, 433 (CCPA 1977) citing *In re Brown*, 59 CCPA 1036, 459 F.2d 531, 173 USPQ 685 (1972). Further, see MPEP §2113, "Even though product-by process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In the instant case, the '557 patent teaches hematopoietic stem cells, which fulfill the definition of a self-renewing, multipotent, slow-cycling. The '557 patent teaches a method of obtaining an enriched population of HSCs using stem cell specific markers, including CD34 (as required by the claims).

Schreiber is provided as evidence that hematopoietic stem cells express alpha-6-integrin (see p. 1494, col. 1, Introduction, ¶3). Accordingly, it would be an inherent property of the hematopoietic stem cells taught by the '557 patent to express alpha-6-integrin.

Akashi is provided as evidence that hematopoietic stem cells express transcription factor 3 (TCF3) (See Figure 4A and p. 388, col. 1, 1st full ¶). Accordingly, it would be an inherent property that the HSCs taught by the '557 patent would express TCF3.

Regarding the limitations of claims 3-5, these claims recite properties of the cell. These properties would be inherent to the stem cell. "Products of identical

chemical composition can not have mutually exclusive properties.” A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990).

Claims 2-5, 7-16 are rejected under 35 U.S.C. 102(a) as being anticipated by Tumbar *et al.* (*Science*, 303: 359-363, January 2004, available online December 11, 2003). This is a new ground of rejection necessitated by Applicants’ amendment to the claims.

Regarding claim 2, Tumbar teach label-retaining cells (LRC) that mark the skin stem cell niche (see abstract). Tumbar teach that these cells express CD34 and alpha-6-integrin (p. 360, col. 2, 2nd ¶). The properties recited in claims 3-5 are inherent in the cells taught by Tumbar (see above).

Regarding claims 7, 9-14, Tumbar further teach engineering transgenic mice that expressed histone H2B-GFP controlled by a TRE (tet-responsive) regulatory element. Tumbar teaches that without tet, epithelial cells exhibit GFP fluorescence, but after feeding mice Tet for 4 weeks, only bulge cells retained fluorescence, which Tumbar cites as marking bulge stem cells by basis of their slow-cycling properties (pp. 359-360, bridging ¶). Tumbar teaches using flow-sorting of single cell suspensions from chased transgenic mouse skin, in order to separate cells by GFP^{high} and GFP^{low} cells and state that GFP^{high} cells were enriched in CD34 and corresponded in fluorescence intensity to bulge cells (see p. 360, col. 2-3, bridging ¶). Tumbar teaches that analysis of the decay of the H2b-BFP signal showed that GFP fluorescence markedly decreased after 1 week of chase and continued to be lost progressively during the 4-8 week period, concomitant with expected cell divisions. See p. 17 of the Supplement. Accordingly, Tumbar teach the steps required in claim 7 and necessarily produce the cells of claims 9-14.

Regarding claims 15-16, Tumbar teaches that the GFP^{high} cells were capable of forming colonies (p. 360, col. 2, last full ¶).

Accordingly, Tumbar anticipate the claims.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35

U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tumbar *et al.* (**Science**, 303: 359-363, January 2004, available online December 11, 2003 when taken with US Pat No. 5,665,557 (Filed November, 1994; Issued September 9, 1997). This is a new ground of rejection necessitated by Applicants' amendment to the claims.

Tumbar teach label-retaining cells (LRC) that mark the skin stem cell niche (see abstract). Tumbar teach that these cells express CD34 and alpha-6-integrin (p. 360, col. 2, 2nd ¶).

Tumbar do not specifically teach a method for isolating their cells using CD34 and a selected slow-cycling cell marker expressed by the cell, wherein the marker is selected from the group consisting of TCF3, TCF4, alpha 6 integrin, G-protein coupled receptor, and BMPR1A.

However, prior to the time of the claimed invention, the '557 patent teaches methods of obtaining an enriched population of HSCs by using specific HSC antibodies (*e.g.*, CDw109, CD34). Thus, the '577 patent teaches methods to sort stem cells using specific markers.

Accordingly, in view of the combined art, it would have been obvious to the skilled artisan to utilize the methods taught by the '557 patent, in order to isolated specific cells, as taught by Tumbar, using markers expressed by those cells, including CD34, alpha 6 integrin, etc., with a reasonable expectation of success. One of skill in the art would have been sufficiently motivated to sort cells using the '557 patent in view of Tumbar's teachings that their LRC cells expressed high levels of CD34 and alpha-6 integrin (see p. 360, col. 2, 1st ¶ and Figure 2B). Accordingly, the method taught by the '557 patent would be an efficient way to isolate the stem cells taught by Tumbar.

Thus, the claimed invention, as a whole, is clearly *prima facie* obvious in the absence of evidence to the contrary.

Claims 7 and 9 stand rejected under 35 U.S.C. 103(a) as being unpatentable over US Pat. No. 5,639,618 (Filed May 13, 1994, Issued June 17, 1997, IDS) when taken with Strathdee *et al.* (**Gene**, 229: 21-29, 1999), Bohl *et al.* (**Nat. Med.**, 3(3): 229-305, 1997) when taken with Mahmud *et al.* (**Blood**, 97(10): 3061-3068, 2001) and US Pat. No. 6,485,971 (filed September 18, 2000, Issued November 26, 2002).

Applicants' Arguments. Applicants traverse the rejection and argue that there are considerable differences between the present invention and the combined teachings of the cited references. Applicants argue that the Examiner has acknowledged that the '618 document, Strathdee and Bohl do not teach the inactivating steps of d)-g) and that the Examiner has relied upon Mahmud to teach that pluripotent cells are slow-cycling and maintain higher levels of reporter protein, and the '971 document provides clear guidance for separating cells that have higher versus lower levels of protein expression. However, Applicants argue that Mahmud and the '971 do not arrive at the claimed invention. See pages 8-9 of the Response.

Mahmud, Applicants argue, teach the incorporation of BrdU into pluripotent HSCs to analyze the replicative history of the same, and the '971 patent appears to teach separation of cells based upon the level of transferring receptor, EGFR, IGFR and keratinocyte growth factor receptor expressed by a cell, and this does not constitute sufficient guidance for the steps of d)-g) of the instant claims. In particular, Applicants argue that collectively, these references would have suggested to the skilled artisan that dye exclusion in combination with cell surface protein can be used to sort cells, but neither of these references would have suggested that cells could be sorted based upon the amount of the reporter protein present in each cell in the manner presently claimed, because nowhere is there the

suggestion that cells can be sorted based upon cell cycle-mediated dilution or retention of a reporter gene. See pages 9-10 of the Response.

Applicants argue that in the instant case, the Examiner has not set forth an articulated rationale for combining the disparate teachings of the cited references in order to arrive at the claimed invention. Applicants argue that the mere conclusory statement that one would have been motivated to inactivate the regulatable transcription factor and select for slow-cycling stem cells by allowing the cells to divide, and selecting cells that contain a higher level of reporter protein expression based upon the teachings of Mahmud and the '971 document is simply not supported by the teachings of the references. See pages 10-11 of the Response.

Response to Arguments. These arguments have been considered but not persuasive. In the instant case, the Examiner contends that the combination of art as a whole is sufficient to arrive at the claimed invention. In particular, the guidance for using a reporter protein in cell sorting to isolate a specific type of stem cell is found in the '618 document. Strathdee and Bohl provide guidance to show that the Tet system would be useful in regulating gene expression in stem cells. Thus, addition of a reporter gene, such as GFP, which is taught in the '618 document, would be fully recognized by the skilled artisan as a method to monitor cell-specific expression in order to separate the cells using the cell sorting methods taught by the '618 document. Thus, it would be obvious that the vectors taught by Strathdee and Bohl could be modified to incorporate a reporter gene for use in the sorting methods taught by the '618 patent.

Mahmud provide guidance to show that the skilled artisan would recognize that stem cells are considered slow-cycling cells, and that the enriching steps, such as those taught in the '971 document are also known in the art (col. 3, lines 49+-col. 4, lines 1-12, for example). Thus, Mahmud teach that stem cells are slow-cycling, which would clearly maintain higher levels of reporter protein than cells that are dividing, and the '971 document provides clear guidance as to how to separate cells

that have higher versus lower levels of protein expression. One of skill in the art would be further motivated, in view of the teachings of Mahmud and the '971 document, to inactivate the regulatable transcription factor (by, for example, the withdrawal of doxycycline in the case of using the Tet system), and select for slow-cycling stem cells by allowing the cells to divide, and selecting cells that contain a higher level of reporter protein expression. The fact that stem cells are slow-cycling cells, withdrawal of doxycycline, and then allowing the slow-cycling cells to divide would provide a distinction in concentration of reporter gene when compared to non-slow cycling cells. The Examiner contends that each step of the claimed invention is obvious over the cited art of record and the rejection is maintained.

Rejection

The '618 document teaches methods of isolating a lineage-specific stem cell *in vitro* by transfecting an lineage specific stem cell with a construct comprising a regulatory region of a lineage specific gene operably linked to a DNA encoding a reporter gene and separating the cells which express the reporter protein from other cells in the culture (see Abstract). The '618 document teaches that enhancer specificity will direct expression of the surface protein at the desired stage of isolation and FACS will allow the efficient isolation of the desired stem cell (col. 4, lines 15-22). Thus, as a whole, the '618 document provides guidance for specifically isolating stem cells utilizing a promoter that is active in stem cells and using known cell sorting techniques.

However, the '618 document does not specifically teach that the nucleic acid sequence(s) that introduced into the stem cell encode a regulatable transcription factor operably linked to the stem cell specific promoter (claim 7, part a), and a nucleic acid sequence encoding a nucleic acid sequence encoding a reporter protein operably linked to a regulated promoter to which the regulatable transcription factor binds (claim 7, part b) such that upon expression of the stem cell specific

promoter, the regulatable transcription factor increases expression of the reporter protein (claim 7, part c). However, prior to the time of filing, Strathdee teaches using the tetracycline-responsive system to provide efficient, tightly regulated, inducible gene expression system, using a bi-directional expression vector wherein the TK promoter is used to direct expression of the rtTA or tTA transactivator and the CMV element is used to direct cDNA expression. In particular, gene expression can be efficiently switched on and off using doxycycline and a selectable marker can be incorporated into the vector (see Abstract). Strathdee suggest that their system can be used to confine gene expression in a defined cell type (p. 29, second to last sentence). Additionally Bohl teach using tetracycline regulation of gene expression for muscle-specific expression of mouse erythropoietin (Epo) cDNA using a two vector system and found that gene expression increased 200 fold in response to myogenic cell differentiation and doxycycline stimulation (Abstract). Bohl teach that these vectors efficiently allow for cotransduction of primary cells and that the control of rtTA expression from a skeletal muscle specific promoter prevents the accumulation of the potentially toxic protein in vector-producing cells, and that the resultant cells stably expressed the vector over time (p. 303, 1st col., Efficient cotransduction of primary cells).

Neither the '618 document, Strathdee or Bohl specifically teach inactivating the regulatable transcription factor so that expression of the reporter protein is decreased, incubation of the cell for a sufficient amount of time so that the cell goes through one or more cell cycles to generate a population of cells, detecting the amount of reporter in the population and then sorting the population of cells by the amount of reporter protein present in each cell, wherein sorted cells containing increased levels of the reporter is indicative of self-renewing, multipotent, slow-cycling cells. However, prior to the time of filing, Mahmud *et al.* provide specific guidance to show that multipotent stem cells, such as hematopoietic stem cells, are considered slow-cycling cells (see Abstract). Additionally, the concept of separating

rapidly dividing cells from slow-cycling cells is known in the art. For example, the '971 document discusses enrichment methods for keratinocyte stem cells, teaching that one may select a first population of cells from a partially enriched pool, and then provide a second enrichment step by separating cells with high and low binding levels from those which have low binding levels, using, for example antibodies and FACS techniques (col. 3, lines 49+-col. 4, lines 1-12, for example). Accordingly, Mahmud teach that pluripotent cells are slow-cycling, which would clearly maintain higher levels of reporter protein than cells that are dividing, and the '971 document provides clear guidance as to how to separate cells that have higher versus lower levels of protein expression.

Accordingly, the '618 document provides guidance with regard to isolation of lineage-specific cells, and both Strathdee and Bohl teach methods of inducible gene expression that can efficiently be switched on and off, and avoid the art-recognized problem of cellular toxicity. Additionally, Strathdee provide motivation for utilizing this type of system in specific cell types and Bohl provide guidance to show that using a cell-specific promoter, one can efficiently express a gene of interest in a cell type of interest. Mahmud and the '971 document provide sufficient guidance to show that one of skill in the art would be readily apprised that stem cells are considered slow-cycling, and the '971 document provides sufficient guidance to separate cells based on the amount of reporter gene expression.

Thus, it would be obvious to one of skill in the art, to modify the '618 document to utilize a vector system such as that taught by Strathdee or Bohl, utilizing a regulatable transcription factor operably linked to a cell-specific (for example, a stem cell specific) promoter, and a nucleic acid sequence encoding a reporter protein operably linked to a regulated promoter in which the regulatable transcription binds, using, for example, the tetracycline responsive expression system taught by both Strathdee and Bohl, and utilizing a reporter protein, such as any of those suggested by the '618 document, in order to FACS sort a protein, with a

reasonable expectation of success. One of ordinary skill in the art would have been sufficiently motivated to make this modification in view of the teachings of both Strathdee and Bohl, who suggest utilizing these techniques in lineage-specific cells, and teach that utilizing their systems overcome the art-recognized problem of cellular toxicity (see, for example, Strathdee at p. 22, 1st col., 1st full ¶). One of skill in the art would be further motivated, in view of the teachings of Mahmud and the '971 document, to inactivate the regulatable transcription factor (by, for example, the withdrawal of doxycycline in the case of using the Tet system), and select for slow-cycling stem cells by allowing the cells to divide, and selecting cells that contain a higher level of reporter protein expression. One of ordinary skill in the art would have been sufficiently motivated to make this modification in order to produce substantially pure populations of stem cells. Although the pieces of art cited do not all recite isolation of the same types of stem cells, they provide sufficient guidance to show that the art is replete in methods for isolation and purification of stem cells, using various techniques that would be readily available to the skilled artisan.

Thus, the claimed invention, as a whole, is clearly *prima facie* obvious in the absence of evidence to the contrary.

Claims 8, 10-14 stand rejected under 35 U.S.C. 103(a) as being unpatentable over US Pat. No. 5,639,618 (Filed May 13, 1994, Issued June 17, 1997, IDS) when taken with Strathdee *et al.* (**Gene**, 229: 21-29, 1999), Bohl *et al.* (**Nat. Med.**, 3(3): 229-305, 1997) when taken with Mahmud *et al.* (**Blood**, 97(10): 3061-3068, 2001) and US Pat. No. 6,485,971 (filed September 18, 2000, Issued November 26, 2002) as applied to claims 7 and 9 above, and further in view of US Pat No. 5,665,557 (Filed November, 1994; Issued September 9, 1997).

Applicants provide the same arguments as above, which have been addressed.

The '618 document, Strathdee, Bohl, Mahmud and the '971 document are discussed above. They do not specifically teach sorting the population of cells based on the presence of CD34 and the amount of a selected slow-cycling cell marker. However, prior to the time of the claimed invention, the '557 document teaches obtaining an enriched population of hematopoietic stem cells by obtaining a population of human hematopoietic cells, separation of hematopoietic cells from a source, separating a subpopulation of cells utilizing a CDw109 antibody, and then using an additional marker to separate the cells, such as CD34, Thy-1 and rho. The limitations of claims 11-14 are considered inherent properties of the cell that would be isolated.

Accordingly, it would have been obvious to modify the combined teachings of the '618 document, Strathdee, Bohl, Mahmud and the '971 document, as outlined above, to separate a population of cells based on the presence of CD34 and a selected slow-cycling cell marker, such as any taught by the '577 document, with a reasonable expectation of success. One of ordinary skill in the art would have been sufficiently motivated to make this modification to produce a substantially pure population of hematopoietic stem cells.

Thus, the claimed invention, as a whole, is clearly *prima facie* obvious in the absence of evidence to the contrary.

Claims 15-16 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Strathdee *et al.* (**Gene**, 229: 21-29, 1999), Bohl *et al.* (**Nat. Med.**, 3(3): 229-305, 1997) when taken with Mahmud *et al.* (**Blood**, 97(10): 3061-3068, 2001) and US Pat. No. 6,485,971 (filed September 18, 2000, Issued November 26, 2002) and US Pat No. 5,665,557 (Filed November, 1994; Issued September 9, 1997) as applied to claims 7-14 above, and further in view of US Pat. No. 5,861,315 (Filed October 16, 1996; Issued January 19, 1999).

Applicants provide the same arguments as above, which have been addressed.

Strathdee, Bohl, Mahmud, the '971 document, the '557 document are detailed above. The combined art does not specifically teach or suggest a clonal population that comprises the cells of claims 9 or 10. However, prior to the time of the claimed invention, the '315 document teaches the clonal culture of CD34+ hematopoietic stem cells (col. 6, lines 5+).

Accordingly, it would have been obvious to the skilled artisan to utilize the combined art of Strathdee, Bohl, Mahmud, the '971 document, the '557 document to produce sorted cells that are self-renewing, multipotent, slow-cycling cells (claim 7), and particularly cells that are sorted based on the presence of CD32 and the amount of a selected slow-cycling cell marker (claim 8), and to then produce a clonal population of these cells, with a reasonable expectation of success. One of ordinary skill in the art would have been motivated to make a clonal population of cells, such as hematopoietic stem cells for the methylcellulose assay such as that detailed in the '315 patent to analyze the differentiation potential of the cells. Additionally, a clonal population would ensure uniformity in the cell population, which could then be used for other purposes, such as gene therapy.

Thus, the claimed invention, as a whole, is clearly *prima facie* obvious in the absence of evidence to the contrary.

Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thaian N. Ton whose telephone number is (571)272-0736. The examiner can normally be reached on 9-5:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Thaian N. Ton/
Primary Examiner, Art Unit 1632